DiscGenics is focused on developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine.
Location: United States, Utah, Salt Lake City
Total raised: $114M
Investors 1
| Date | Name | Website |
| - | Medical In... | medicalinc... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 17.02.2021 | - | $50M | - |
| 23.10.2020 | Series C | $50M | - |
| 26.09.2017 | Series B | $14M | - |
Mentions in press and media 10
| Date | Title | Description |
| 23.07.2024 | DiscGenics Announces US FDA Approval to Proceed with Phase III Clinical Evaluation of Allogeneic, Injectable Disc Progenitor Cell Therapy for Symptomatic Lumbar Degenerative Disc Disease | Receives FDA acceptance on Phase III clinical protocols for parallel pivotal and confirmatory trials Achieves alignment with FDA on Chemistry, Manufacturing, and Controls (CMC) aspects of Phase III program SALT LAKE CITY, July 23, 2024 /PRN... |
| 24.01.2023 | DiscGenics Announces Positive Two-Year Clinical Data from Study of Discogenic Progenitor Cell Therapy for Degenerative Disc Disease | DiscGenics, a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, announced positive two-year clinica... |
| 09.09.2020 | DiscGenics Appoints Former Medtronic Spine and Biologics Finance Executive as First Chief Financial Officer | |
| 27.08.2020 | DiscGenics Raises $50M in Series C Funding | DiscGenics, Inc., a Salt Lake City, UT-based clinical stage biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, raised $50m in ... |
| 25.08.2020 | Biotech startup DiscGenics raises $50 Million in Series C funding to develop regenerative cell-based therapies for treatment of chronic back pain | Degenerative disc disease (DDD) is a chronic condition that is characterized by inflammation and breakdown of the extracellular matrix within the intervertebral disc. DDD often results in chronic low back pain, which is a leading cause of d... |
| 25.08.2020 | DiscGenics Raises $50 Million in Series C Funding | SALT LAKE CITY, Aug. 25, 2020 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the s... |
| 25.08.2020 | DiscGenics Raises $50 Million in Series C Funding USA - English Japanese English | |
| 26.09.2017 | DiscGenics Raises $14M in Series B Financing | DiscGenics, Inc., a Salt Lake City, UT-based clinical stage regenerative medicine company focused on developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, closed a $1... |
| 21.05.2014 | California payer one of 9 healthcare companies on RedHerring Top 100 list | Last year the company did a study of 120,000 employees enrolled in its program over a 3-year period. SeeChange reported these results: Close to 80% of the incentive program members earned points, with slightly increased and sustained engage... |
| - | California payer one of 9 healthcare companies on RedHerring Top 100 list | SeeChange Health has won a Red Herring Top 100 North America Award. The award recognizes private companies from North America for innovation and new technology in their respective industries. SeeChange Health offers Health Insurance and Hea... |